Reasoning
The ClinGen PTEN VCEP permits PS4 Strong when the prevalence of the variant in affected individuals is significantly increased compared with controls. The available case evidence contains no variant-specific affected-versus-control counts, case frequency, matched-ancestry gnomAD frequency, odds ratio, confidence interval, or specificity score. The literature packet's PS4 candidates were not variant-specific in the available evidence; the extracted full text for PMID:35924163 states that PTEN, c.975del, and p.(D326Tfs*18) were not reported. Therefore, PS4 cannot be evaluated from the available evidence, and no case-control comparison or numeric inequality can be made.
VCEP rule
Probands with specificity score 4-15.5 (see text) OR The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls.
Evidence considered
- ClinGen PTEN VCEP PS4 Strong rule: affected-individual prevalence must be significantly increased compared with controls; the bundle provides no variant-specific case-control counts, frequencies, odds ratio, 95% confidence interval, or specificity score.
- PMID:35924163 paper extract: the consensus paper does not report PTEN, c.975del, or NP_000305.3:p.(D326Tfs*18), and provides no variant-specific clinical or population-frequency information.
Still missing
- Variant-specific affected and control counts or frequencies, including matched-ancestry population controls, are needed to calculate an odds ratio and 95% confidence interval.
- A PTEN VCEP specificity score is not available for this case.
Sources